JP6811014B2 - Ｂ型肝炎ウイルスに対するワクチン - Google Patents

Ｂ型肝炎ウイルスに対するワクチン Download PDF

Info

Publication number
JP6811014B2
JP6811014B2 JP2015548778A JP2015548778A JP6811014B2 JP 6811014 B2 JP6811014 B2 JP 6811014B2 JP 2015548778 A JP2015548778 A JP 2015548778A JP 2015548778 A JP2015548778 A JP 2015548778A JP 6811014 B2 JP6811014 B2 JP 6811014B2
Authority
JP
Japan
Prior art keywords
seq
peptide
amino acid
acid sequence
hbv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015548778A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016505589A (ja
JP2016505589A5 (cg-RX-API-DMAC7.html
Inventor
ヴィクター ギルバート ジョルジュ，バートランド
ヴィクター ギルバート ジョルジュ，バートランド
ブラッドリー ブラウン，カールトン
ブラッドリー ブラウン，カールトン
Original Assignee
アルティミューン ユーケー リミテッド
アルティミューン ユーケー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルティミューン ユーケー リミテッド, アルティミューン ユーケー リミテッド filed Critical アルティミューン ユーケー リミテッド
Publication of JP2016505589A publication Critical patent/JP2016505589A/ja
Publication of JP2016505589A5 publication Critical patent/JP2016505589A5/ja
Application granted granted Critical
Publication of JP6811014B2 publication Critical patent/JP6811014B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2015548778A 2012-12-24 2013-12-20 Ｂ型肝炎ウイルスに対するワクチン Expired - Fee Related JP6811014B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1223386.2 2012-12-24
GBGB1223386.2A GB201223386D0 (en) 2012-12-24 2012-12-24 Vaccine
PCT/GB2013/053410 WO2014102540A1 (en) 2012-12-24 2013-12-20 Vaccines against hepatitis b virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018189011A Division JP7187237B2 (ja) 2012-12-24 2018-10-04 Ｂ型肝炎ウイルスに対するワクチン

Publications (3)

Publication Number Publication Date
JP2016505589A JP2016505589A (ja) 2016-02-25
JP2016505589A5 JP2016505589A5 (cg-RX-API-DMAC7.html) 2017-02-09
JP6811014B2 true JP6811014B2 (ja) 2021-01-13

Family

ID=47682590

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015548778A Expired - Fee Related JP6811014B2 (ja) 2012-12-24 2013-12-20 Ｂ型肝炎ウイルスに対するワクチン
JP2018189011A Active JP7187237B2 (ja) 2012-12-24 2018-10-04 Ｂ型肝炎ウイルスに対するワクチン
JP2021025254A Active JP7235785B2 (ja) 2012-12-24 2021-02-19 Ｂ型肝炎ウイルスに対するワクチン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018189011A Active JP7187237B2 (ja) 2012-12-24 2018-10-04 Ｂ型肝炎ウイルスに対するワクチン
JP2021025254A Active JP7235785B2 (ja) 2012-12-24 2021-02-19 Ｂ型肝炎ウイルスに対するワクチン

Country Status (12)

Country Link
US (3) US10300132B2 (cg-RX-API-DMAC7.html)
EP (2) EP3995146A1 (cg-RX-API-DMAC7.html)
JP (3) JP6811014B2 (cg-RX-API-DMAC7.html)
KR (3) KR102625645B1 (cg-RX-API-DMAC7.html)
CN (2) CN114028553A (cg-RX-API-DMAC7.html)
CA (1) CA2895459A1 (cg-RX-API-DMAC7.html)
DK (1) DK2935313T3 (cg-RX-API-DMAC7.html)
EA (1) EA201591213A1 (cg-RX-API-DMAC7.html)
ES (1) ES2906110T3 (cg-RX-API-DMAC7.html)
GB (1) GB201223386D0 (cg-RX-API-DMAC7.html)
PL (1) PL2935313T3 (cg-RX-API-DMAC7.html)
WO (1) WO2014102540A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021098711A (ja) * 2012-12-24 2021-07-01 アルティミューン ユーケー リミテッド Ｂ型肝炎ウイルスに対するワクチン

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0408164D0 (en) * 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB201022147D0 (en) * 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
WO2016020538A1 (en) * 2014-08-08 2016-02-11 Transgene Sa Hbv vaccine and antibody combination therapy to treat hbv infections
CN106610423A (zh) * 2015-10-26 2017-05-03 复旦大学 评价疫苗疗效的细胞免疫学检测试剂盒及其储存方法
HUE065176T2 (hu) 2016-06-02 2024-05-28 Ultimovacs Asa Vakcina kombinációban immunellenõrzõpont inhibitorral felhasználásra rák kezelésében
JP7115803B2 (ja) 2016-06-20 2022-08-09 アイエスエー ファーマシューティカルズ ビー．ヴイ． ペプチドワクチン製剤
WO2019126120A1 (en) * 2017-12-19 2019-06-27 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis b virus (hbv) vaccines
CA3096056A1 (en) * 2018-04-04 2019-10-10 Altimmune, Inc. T-cell inducing vaccine composition combinations and uses thereof
WO2020145901A1 (en) * 2019-01-11 2020-07-16 Agency For Science, Technology And Research Use of hla-a*11:01-restricted hepatitis b virus (hbv) peptides for identifying hbv-specific cd8+ t cells
US20220324916A1 (en) * 2019-06-18 2022-10-13 Janssen Sciences Ireland Unlimited Company Hepatitis B Virus (HBV) Vaccines and Uses Thereof
MX2022002270A (es) * 2019-08-29 2022-03-22 Vir Biotechnology Inc Vacunas contra el virus de la hepatitis b.
KR20220143812A (ko) 2019-12-07 2022-10-25 아이에스에이 파마슈티컬즈 비.브이. B형 간염 바이러스와 관련된 질병의 치료
EP4087605A1 (en) * 2020-01-09 2022-11-16 Virion Therapeutics, LLC Adenoviral vectors encoding hepatitis b viral antigens fused to herpes virus glycoprotein d and methods of using the same
WO2023085956A1 (en) * 2021-11-09 2023-05-19 Avalia Immunotherapies Limited Novel therapeutic vaccines

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA926440B (en) * 1991-08-26 1993-06-07 Scripps Research Inst Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus.
US6607727B1 (en) * 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
ES2187530T3 (es) * 1993-08-02 2003-06-16 Scripps Research Inst Peptidos para reducir respuestas de linfocito t ctitotoxicos al virus de la hepatitis b.
CA2422506A1 (en) * 2000-09-08 2002-03-14 Epimmune Inc. Inducing cellular immune responses to hepatitis b virus using peptide and nucleic acid compositions
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
US10076570B2 (en) * 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
GB201022147D0 (en) 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
GB201223386D0 (en) * 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021098711A (ja) * 2012-12-24 2021-07-01 アルティミューン ユーケー リミテッド Ｂ型肝炎ウイルスに対するワクチン
CN114028553A (zh) * 2012-12-24 2022-02-11 奥提姆尼英国有限公司 包括免疫原性肽组合的药物组合物
JP7235785B2 (ja) 2012-12-24 2023-03-08 アルティミューン ユーケー リミテッド Ｂ型肝炎ウイルスに対するワクチン

Also Published As

Publication number Publication date
JP7235785B2 (ja) 2023-03-08
US10300132B2 (en) 2019-05-28
US11918645B2 (en) 2024-03-05
KR102497063B1 (ko) 2023-02-06
EP3995146A1 (en) 2022-05-11
US20200016263A1 (en) 2020-01-16
EA201591213A1 (ru) 2016-02-29
KR20230021771A (ko) 2023-02-14
GB201223386D0 (en) 2013-02-06
CA2895459A1 (en) 2014-07-03
PL2935313T3 (pl) 2022-05-02
EP2935313A1 (en) 2015-10-28
JP2021098711A (ja) 2021-07-01
CN104903343A (zh) 2015-09-09
KR102358621B1 (ko) 2022-02-03
JP2016505589A (ja) 2016-02-25
CN114028553A (zh) 2022-02-11
EP2935313B1 (en) 2021-11-24
US20160106830A1 (en) 2016-04-21
WO2014102540A1 (en) 2014-07-03
US11382969B2 (en) 2022-07-12
JP2019034946A (ja) 2019-03-07
DK2935313T3 (da) 2022-02-28
ES2906110T3 (es) 2022-04-13
JP7187237B2 (ja) 2022-12-12
KR20220019846A (ko) 2022-02-17
KR102625645B1 (ko) 2024-01-15
KR20150098676A (ko) 2015-08-28
US20230090379A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
JP7235785B2 (ja) Ｂ型肝炎ウイルスに対するワクチン
JP3738395B2 (ja) Ｈｌａ−制限型ｂ型肝炎ウィルスのｃｔｌエピトープ
JP3650110B2 (ja) Ｂ型肝炎ウイルスに対する細胞毒性ｔリンパ球応答を誘発するためのペプチド
US20160199469A1 (en) Oncology vaccine
US20090028874A1 (en) Synthetic Protein as Tumor-Specific Vaccine
Shi et al. Therapeutic polypeptides based on HBcAg18-27 CTL epitope can induce antigen-specific CD8+ CTL-mediated cytotoxicity in HLA-A2 transgenic mice
JP2010029217A (ja) Ｈｉｖ特異的ｃｔｌを誘導し得るペプチド及び該ペプチドを含む抗ａｉｄｓ予防・治療剤
EP2987502B1 (en) Peptide adjuvants
HK40067424A (en) Pharmaceutical compositions comprising combination of immunogenic peptides
CN114560917A (zh) SARS-CoV-2编码蛋白来源的T细胞表位多肽TFKVSIWNL及其应用
BR112015015198B1 (pt) Composição farmacêutica, e, vetor de fluorcarbono
EP4282429A1 (en) Multivalent covid-19 vaccines based on adenoviral vectors
Wijayadikusumah An evaluation of charged Pam2Cys-based lipopeptides as novel adjuvants for subunit-based vaccines

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20160107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180305

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181004

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20181004

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20181012

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20181016

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20181214

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20181218

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20190409

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20190611

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20190806

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200107

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20200317

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200407

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200917

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20200929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201016

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20201104

C302 Record of communication

Free format text: JAPANESE INTERMEDIATE CODE: C302

Effective date: 20201106

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20201208

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20201208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201214

R150 Certificate of patent or registration of utility model

Ref document number: 6811014

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees